| Ytd | -20.39% | |
| 1y | -59.82% |
| Open | 0.67 | Prev Close | 0.64 | Low | 0.66 | High | 0.70 | Mkt Cap | 8.41M |
| Vol | 24.08K | Avg Vol | 99.58K | EPS | -1.54 | P/E | -0.44 | Forward P/E | -3.08 |
| Beta | 1.74 | Short Ratio | 0.55 | Inst. Own | 43.85% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-15 | 50-d Avg | 0.72 | 200-d Avg | 0.87 | 1yr Est | 15.67 |
APRE News
/PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary
Next clinical data update from the ongoing Phase 1 dose escalation ACESOT-1051 trial anticipated at
Next clinical data update from the ongoing Phase 1 dose escalation ACESOT-1051 trial anticipated at
Aprea Therapeutics, Inc. (Nasdaq: APRE) ("Aprea", or the "Company"), a clinical-stag
Presentation highlights early clinical activity from ACESOT-1051, including partial responses and st
Aprea Therapeutics (APRE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism ab
Wedbush analyst Robert Driscoll maintains Aprea Therapeutics (NASDAQ:APRE) with a Outperform and
Aprea Therapeutics (NASDAQ:APRE) reported quarterly losses of $(0.22) per share which beat the analy
DOYLESTOWN, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”,
Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Ana
Pre-Market Stock Futures: Futures are trading modestly higher after a blowout midweek rally spurred
Oppenheimer analyst Matthew Biegler initiates coverage on Aprea Therapeutics (NASDAQ:APRE) with a
Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage
DOYLESTOWN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”
DOYLESTOWN, Pa., April 01, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”
Financing led by Soleus Capital with participation from Vestal Point Capital, Squadron Capital Manag
Confirmed partial response at 220 mg indicates anti-tumor activity of APR-1051 in biomarker-defined
Aprea Therapeutics (NASDAQ: APRE - Get Free Report) will likely be releasing its Q4 2025 results bef
DOYLESTOWN, Pa., March 16, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”
Aprea Therapeutics (NASDAQ: APRE) shares are trading higher on Wednesday as the company announced ad
Tumor Shrinkage of 50% and significant CA-125 biomarker reduction observed at 220 mg dose level Pati
DOYLESTOWN, Pa., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”
New patents granted in 2025 in Australia and Japan bolster global IP coverage for Aprea's WEE1 and A
Seasoned oncology drug development leader joins following early clinical proof-of-concept for WEE1 i
Approximately 50% reduction in target lesion and greater than 90% decrease in CA-125 observed in end
DOYLESTOWN, Pa., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”,
APRE, NFE and CZR have been added to the Zacks Rank #5 (Strong Sell) List on January 19, 2026.
On Wednesday, 129 stocks made new 52-week lows.
On Monday, 76 companies set new 52-week lows.
On Monday, 89 stocks made new 52-week lows.
On Friday, 469 companies hit new 52-week lows.
Friday's session saw 75 companies set new 52-week lows.
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares surged 56.6% to settle at $19.10 on Friday.
Gainers Snail, Inc. (NASDAQ: SNAL) shares jumped 74.9% to $3.9350 after the company announced a $
During Wednesday's trading, 517 companies set new 52-week lows.